3 studies found for:    17229040 [PUBMED-IDS]
Show Display Options
Rank Status Study
1 Active, not recruiting Long-Term Safety Follow-up Study of Cysteamine Bitartrate Delayed-release Capsules (RP103)
Condition: Cystinosis
Intervention: Drug: Cysteamine Bitartrate Delayed-release Capsules (RP103)
2 Completed Pilot Study of Safety, Tolerability, Pharmacokinetics/Pharmacodynamics (PK/PD) of RP103 Compared to Cystagon® in Patients With Cystinosis
Condition: Cystinosis
Interventions: Drug: Cystagon® (Cysteamine Bitartrate) Capsules: 150 mg/50 mg;   Drug: RP103
3 Completed Phase 3 Study of Cysteamine Bitartrate Delayed-release (RP103) Compared to Cystagon® in Patients With Cystinosis
Condition: Cystinosis
Interventions: Drug: Cystagon® (Cysteamine Bitartrate);   Drug: Cysteamine Bitartrate Delayed-release Capsules (RP103)

Indicates status has not been verified in more than two years